A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of CT-P55 with Cosentyx in Patients with Moderate to Severe Plaque Psoriasis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513348-27-00

Acronym

CT-P55 3.1

Enrollment

375

Registered

2025-02-17

Start date

2025-05-09

Completion date

Unknown

Last updated

2025-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plaque psoriasis

Brief summary

Percent change from baseline in PASI score at Week 8

Interventions

DRUGCosentyx 150 mg solution for injection in pre-filled syringe

DRUGCT-P55

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percent change from baseline in PASI score at Week 8	—

Countries

Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026